课题基金 / 基金详情

Developing GalR 1/2 Agonists to Treat Nerve Gas Induced Seizure

Developing GalR 1/2 Agonists to Treat Nerve Gas Induced Seizure
开发 GalR 1/2 激动剂来治疗神经毒气引起的癫痫发作
批准号:
7899875
负责人:
TAMAS BARTFAI
金额:
$94.66万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-16 至 2012-05-31

项目摘要

项目成果

TAMAS BARTFAI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Nerve gases, such as sarin and soman, are classified as weapons of mass destruction. Exposure to organophosphate nerve gases (OP-NG), on the battle field or through terrorist actions like the Tokyo subway incident, leads to convulsions, respiratory failure, and ultimately death. Current prophylaxis and therapy regimen are not effective for OP-NG induced seizures, which usually progress rapidly into status epilepticus, causing profound brain damage. In this proposal, we aim at the development of potent novel anticonvulsants for the treatment of OP-NG induced seizures. This will be achieved by targeting two G-protein coupled receptors (GPCR) in the central nervous system, Gal-R1 and Gal-R2. Both Gal-R1 and Gal-R2 are receptors for the neuropeptide galanin and are expressed at high levels in the hippocampus of the rodent brain. Preclinical studies have shown that signaling through these two galanin receptor subtypes mediates potent anticonvulsant actions. In order to develop potent Gal-R1 and Gal-R2 agonists we embark on three independent approaches: The target profile is as follows: double digit nanomolar affinity for Gal-R1 and or Gal-R2 receptors, agonist activity, at least 50 fold selectivity over other GPCRs and ion channels that are involved in the control of seizure, rapid onset of action, anticonvulsant activity when applied after OP-NG exposure, and no cardiovascular or respiratory side effect and low drug interaction potential. The chemical starting points of this project are excellent, as we have already obtained several Gal-R1 and Gal-R2 ligands and our in vivo experiments demonstrate the anticonvulsant potency of these compounds in several seizure models, when the compounds are applied systemically. Successful development of Gal-R1 and Gal-R2 agonists will not only provide a powerful countermeasure against the terrorist threat but also could bring a new treatment mechanism for seizure/epilepsy. Seizure is a fatal consequence following nerve gas exposure. Counter-terrorist measures proposed here include the identification and development of a novel and potent anticonvulsant agent to protect military personal and civilians from the effect of OP-NG exposure.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Synthesis and biological evaluation of novel pyrimidine derivatives as sub-micromolar affinity ligands of GalR2.
作为 GalR2 亚微摩尔亲和配体的新型嘧啶衍生物的合成和生物学评价。
DOI: 10.1016/j.bmcl.2011.09.033
发表时间: 2011
期刊: Bioorganic & medicinal chemistry letters
影响因子: 2.7
作者: [Sagi,VasudevaNaidu, Liu,Tianyu, Lu,Xiaoying, Bartfai,Tamas, Roberts,Edward]
通讯作者: Roberts,Edward
Developing GalR1/2 Agonists to Treat Nerve Gas Induced Seizure
  • 批准号:
    7696013
  • 项目类别:
  • 资助金额:
    $94.58万
  • 财政年份:
    2008
  • 负责人:
    TAMAS BARTFAI
  • 依托单位:
Developing GalR 1/2 Agonists to Treat Nerve Gas Induced Seizure
  • 批准号:
    7541156
  • 项目类别:
  • 资助金额:
    $94.58万
  • 财政年份:
    2008
  • 负责人:
    TAMAS BARTFAI
  • 依托单位:
Developing GalR 1/2 Agonists to Treat Nerve Gas Induced Seizure
  • 批准号:
    7687924
  • 项目类别:
  • 资助金额:
    $94.47万
  • 财政年份:
    2008
  • 负责人:
    TAMAS BARTFAI
  • 依托单位:
Galanin and GalR2 Receptors in Antidepressant Treatments
  • 批准号:
    7682825
  • 项目类别:
  • 资助金额:
    $39.1万
  • 财政年份:
    2006
  • 负责人:
    TAMAS BARTFAI
  • 依托单位:
国内基金
海外基金
内侧视前区Aplnr/GalR1神经元在炎症性厌食中的作用和环路机制
Spexin/GalR2调节心肌细胞SERCA2a在心力衰竭中的作用及分子机制研究
  • 批准号:
    --
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2022
  • 负责人:
    刘洋
  • 依托单位:
甘丙肽受体1(GALR1)DNA甲基化在生物钟紊乱致多囊卵巢综合征中的作用机制研究
  • 批准号:
    82171623
  • 项目类别:
    面上项目
  • 资助金额:
    59万元
  • 批准年份:
    2021
  • 负责人:
    杜艳芝
  • 依托单位:
基于GALR2/GLUT4信号通路探讨黄芩苷干预胰岛素抵抗的作用及机制
  • 批准号:
    81803792
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    21.0万元
  • 批准年份:
    2018
  • 负责人:
    方彭华
  • 依托单位: